StockNews.com Lowers Quest Diagnostics (NYSE:DGX) to Hold

Quest Diagnostics (NYSE:DGXGet Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

Other research analysts also recently issued research reports about the stock. Piper Sandler upped their price objective on shares of Quest Diagnostics from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Monday, November 6th. Truist Financial upped their price objective on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, December 20th. Bank of America upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $140.00 to $160.00 in a research report on Tuesday, December 12th. Evercore ISI decreased their price objective on shares of Quest Diagnostics from $136.00 to $130.00 in a research report on Wednesday, October 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Quest Diagnostics from $148.00 to $149.00 and gave the stock a “neutral” rating in a research report on Friday, November 17th. Nine investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $146.00.

Read Our Latest Stock Analysis on DGX

Quest Diagnostics Stock Performance

Quest Diagnostics stock opened at $128.42 on Thursday. The company has a 50 day moving average price of $135.67 and a 200-day moving average price of $132.30. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.01 and a current ratio of 1.12. Quest Diagnostics has a fifty-two week low of $119.59 and a fifty-two week high of $150.57. The company has a market capitalization of $14.44 billion, a PE ratio of 19.28 and a beta of 0.91.

Institutional Investors Weigh In On Quest Diagnostics

Hedge funds have recently added to or reduced their stakes in the business. Pacifica Partners Inc. purchased a new position in Quest Diagnostics during the 3rd quarter worth $25,000. NBC Securities Inc. purchased a new position in Quest Diagnostics during the 3rd quarter worth $25,000. Park Place Capital Corp grew its position in Quest Diagnostics by 73.4% during the 2nd quarter. Park Place Capital Corp now owns 189 shares of the medical research company’s stock worth $27,000 after purchasing an additional 80 shares during the last quarter. VisionPoint Advisory Group LLC grew its position in Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares during the last quarter. Finally, Chilton Capital Management LLC purchased a new position in Quest Diagnostics during the 1st quarter worth $28,000. 87.76% of the stock is currently owned by institutional investors and hedge funds.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.